Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511368 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*
A Phase 2 study, sponsored by Myrexis.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00511368 is a Phase 2 study that has completed, run by Myrexis. The registered enrollment target is 92 participants.
The verdict
NCT00511368, a Phase 2 study, has completed, sponsored by Myrexis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate antiretroviral activity of up to five different oral doses administered for two weeks of bevirimat versus placebo in HIV treatment experienced patients, who have documented genotypic resistance to at least one major mutation from the IAS-USA list (2007)of resistance mutations for NRTIs, NNRTIs, or PIs. Patients will also be monitored for side effects, and the pharmacokinetics of bevirimat will be determined.
Interventions
- DRUG matching placebo
- DRUG Bevirimat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00511368
The ClinicalTrials.gov registry entry for NCT00511368 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myrexis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which matching placebo is the first listed.
NCT00511368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00511368 about?
NCT00511368 is a clinical study titled "Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*". The purpose of this study is to evaluate antiretroviral activity of up to five different oral doses administered for two weeks of bevirimat versus placebo in HIV treatment experienced patients, who have documented genotypic resistance to at least one major mutation from the IAS-USA list (2007)of res...
What is the current status of trial NCT00511368?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2006-04. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00511368?
The interventions under investigation include: matching placebo (DRUG), Bevirimat (DRUG).
Who is sponsoring clinical trial NCT00511368?
This trial is sponsored by Myrexis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.